Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.66 |
| ▸ | RELA | Q04206 | 2/20 | 0.66 |
| ▸ | FPR2 | P25090 | 12/20 | 0.58 |
| ▸ | PPARG | P37231 | 6/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589185 | 1.00 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL589186 | 1.00 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL15942746 | 1.00 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL4547582 | 1.00 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL589187 | 1.00 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL4547585 | 1.00 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL18532079 | 0.92 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL29564346 | 0.89 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590253 | 0.89 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590254 | 0.89 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434080-B2 | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs | FORSYTH DENTAL INFIRMARY FOR CHILDREN (US) | 2019-10-08 | — | — | US | disclosed |
| US-20160000741-A1 | Methods for Increasing Oral Osteogenesis Using Lipoxin A4 (LXA4) and Its Analogs | ADA FORSYTH INSTITUTE, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20160000741-A1 | Methods for Increasing Oral Osteogenesis Using Lipoxin A4 (LXA4) and Its Analogs | ADA FORSYTH INSTITUTE, INC. | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434080-B2 | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs | LOXL4, LTA4H, BMP4 | NFKB1 1316/4885NFKB2 1596/4885RELA 2209/4885 |
| US-20160000741-A1 | Methods for Increasing Oral Osteogenesis Using Lipoxin A4 (LXA4) and Its Analogs | LOXL4, LTA4H, BMP4 | NFKB1 1316/4885NFKB2 1596/4885RELA 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.